Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment
Author:
Affiliation:
1. Novartis Pharmaceuticals Corporation East Hanover New Jersey USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1825
Reference29 articles.
1. Global cancer statistics, 2012;Torre LA;CA Cancer J Clin,2015
2. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study;Setiawan VW;Am J Epidemiol,2009
3. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader N;J Natl Cancer Inst,2014
4. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population‐based study;Zhao HY;Cancer Manag Res,2018
5. Metastatic progression of breast cancer: insights from 50 years of autopsies;Cummings MC;J Pathol,2014
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer;Clinical Pharmacokinetics;2024-01-20
2. Ribociclib in newly diagnosed hepatitis B infection: A case report;Frontiers in Oncology;2023-06-08
3. Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials;Clinical Pharmacokinetics;2023-02-17
4. Kisquali (Ribociclib): A promising therapeutic candidate against breast cancer;THE FOURTH SCIENTIFIC CONFERENCE FOR ELECTRICAL ENGINEERING TECHNIQUES RESEARCH (EETR2022);2023
5. Should the Use of Acid Reducing Agents in Conjunction with Ribociclib be Avoided? An Integrated QbD Approach for Assessment of pH-Mediated Interaction;Journal of Chromatographic Science;2022-10-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3